skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Profile of temsirolimus in the treatment of advanced renal cell carcinoma

Review

(2078) Views  (600) Full article downloads

Authors: Michael Staehler, Nicolas Haseke, Wael Khoder, et al

Published Date September 2010 Volume 2010:3 Pages 191 - 196
DOI: http://dx.doi.org/10.2147/OTT.S7657

Michael Staehler, Nicolas Haseke, Wael Khoder, Christian G Stief
Department of Urology, University of Munich, Klinikum Grosshadern, Germany

Abstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trial temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.

Keywords: renal cell cancer, non-clear cell renal cancer, temsirolimus, first-line therapy, overall survival, nephrectomy






Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
CTLA-4 blockade: therapeutic potential in cancer treatments
Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Erratum
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature